EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors

Naoya Maekawa, Satoru Konnai iD, Yumie Asano, Takumi Otsuka, Eri Aoki, Hiroto Takeuchi, Yukinari Kato, Mika K Kaneko, Shinji Yamada iD, Yumiko Kagawa, Maki Nishimura, Satoshi Takagi und 7 weitere

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0281143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Naoya Maekawa und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan. Hauptthemen laut MEDLINE: Adenocarcinoma, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Spontaneous tumors are a major cause of death in cats. Treatment of human tumors has progressed dramatically in the past decade, partly due to the success of immunotherapies using immune checkpoint inhibitors, such as anti-programmed death 1 (PD-1) and anti-PD-ligand 1 (PD-L1) antibodies. However, little is known about the PD-1 pathway and its association with tumor disease in cats. This study investigated the applicability of anti-PD-1/PD-L1 therapy in feline tumors. We first determined the complete coding sequence of feline PD-L1 and PD-L2 , and found that the deduced amino acid sequences of feline PD-L1/PD-L2 share high sequence identities (66–83%) with orthologs in other mammalian species. We prepared recombinant feline PD-1, PD-L1, and PD-L2 proteins and confirmed receptor–ligand binding between PD-1 and PD-L1/PD-L2 using flow cytometry. Next, we established an anti-feline PD-L1 monoclonal antibody (clone CL1Mab-7) to analyze the expression of PD-L1. Flow cytometry using CL1Mab-7 revealed the cell surface expression of PD-L1 in a feline macrophage (Fcwf-4) and five mammary adenocarcinoma cell lines (FKNp, FMCm, FYMp, FONp, and FONm), and showed that PD-L1 expression was upregulated by interferon-γ stimulation. Finally, immunohistochemistry using CL1Mab-7 also showed PD-L1 expression in feline squamous cell carcinoma (5/5, 100%), mammary adenocarcinoma (4/5, 80%), fibrosarcoma (5/5, 100%), and renal cell carcinoma (2/2, 100%) tissues. Our results strongly encourage further investigations of the PD-1/PD-L1 pathway as a potential therapeutic target for feline tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaCarcinoma, Squamous CellAnimalsCatsHumansAntibodies, MonoclonalB7-H1 AntigenImmune Checkpoint ProteinsImmunohistochemistryLigandsProgrammed Cell Death 1 Ligand 2 ProteinCat Diseases

Substanzen

Antibodies, MonoclonalB7-H1 AntigenImmune Checkpoint ProteinsLigandsProgrammed Cell Death 1 Ligand 2 Protein

Autor:innen und Institutionen

  • Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.
  • Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.
  • Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan.
  • Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • North Lab, Sapporo, Japan.

ORCID-Profile: Satoru Konnai, Shinji Yamada, Yasuhiko Suzuki

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development

Zitieren

APA

Maekawa, N., Konnai, S., Asano, Y., Otsuka, T., Aoki, E., Takeuchi, H., Kato, Y., Kaneko, M. K., Yamada, S., Kagawa, Y., Nishimura, M., Takagi, S., Deguchi, T., Ohta, H., Nakagawa, T., Suzuki, Y., Okagawa, T., Murata, S., & Ohashi, K. (2023). Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors. PLOS ONE. https://doi.org/10.1371/journal.pone.0281143

Vancouver

Maekawa N, Konnai S, Asano Y, Otsuka T, Aoki E, Takeuchi H, et al. Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors. PLOS ONE. 2023. doi:10.1371/journal.pone.0281143

BibTeX
@article{Maekawa2023,
  author = {Maekawa, Naoya and Konnai, Satoru and Asano, Yumie and Otsuka, Takumi and Aoki, Eri and Takeuchi, Hiroto and Kato, Yukinari and Kaneko, Mika K and Yamada, Shinji and Kagawa, Yumiko and Nishimura, Maki and Takagi, Satoshi and Deguchi, Tatsuya and Ohta, Hiroshi and Nakagawa, Takayuki and Suzuki, Yasuhiko and Okagawa, Tomohiro and Murata, Shiro and Ohashi, Kazuhiko},
  title = {Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0281143}
}
Kostenlos starten →